Cargando…

HER2-Positive Gastric Cancer: The Role of Immunotherapy and Novel Therapeutic Strategies

Gastric cancer is an aggressive disease with increasing global incidence in recent years. Human epidermal growth receptor 2 (HER2) is overexpressed in approximately 10–20% of gastric cancers. The implementation of targeted therapy against HER2 as part of the standard of care treatment in metastatic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pous, Anna, Notario, Lucía, Hierro, Cinta, Layos, Laura, Bugés, Cristina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10380453/ https://www.ncbi.nlm.nih.gov/pubmed/37511163 http://dx.doi.org/10.3390/ijms241411403

Ejemplares similares

Rectal neuroendocrine carcinoma: case report of a rare entity and perspective review of promising agents
por: Antelo, Gabriela, et al.
Publicado: (2020)

Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors: The Immune Regulatory Role of KRAS and Novel Therapeutic Strategies
por: Cucurull, Marc, et al.
Publicado: (2022)

Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer
por: Ferrando-Díez, Angelica, et al.
Publicado: (2022)

Her2-Positive and Microsatellite Instability Status in Gastric Cancer—Clinicopathological Implications
por: Bermúdez, Ana, et al.
Publicado: (2021)

Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer
por: Wong, Andrea L. A., et al.
Publicado: (2012)

Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer
por: Tsang, R Y, et al.
Publicado: (2012)

Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches
por: Ayoub, Nehad M, et al.
Publicado: (2019)

Immunotherapy for HER-2 positive breast cancer
por: Yang, Tingting, et al.
Publicado: (2023)

Is there a role for immunotherapy in HER2-positive breast cancer?
por: Holgado, Esther, et al.
Publicado: (2018)

HER2-positive gastric cancer
por: Boku, Narikazu
Publicado: (2013)

Targeted and Immunotherapy Approaches in HER2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma: A New Era
por: Radford, Maluki, et al.
Publicado: (2023)

Immunotherapies against HER2-Positive Breast Cancer
por: Duro-Sánchez, Santiago, et al.
Publicado: (2023)

Tailoring DNA Vaccines: Designing Strategies Against HER2-Positive Cancers
por: Marchini, Cristina, et al.
Publicado: (2013)

Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives
por: Agostinetto, Elisa, et al.
Publicado: (2022)

HER2 Inhibition in Gastric Cancer—Novel Therapeutic Approaches for an Established Target
por: Fong, Caroline, et al.
Publicado: (2022)

Antitumor activity of pan‐HER inhibitors in HER2‐positive gastric cancer
por: Yoshioka, Takahiro, et al.
Publicado: (2018)

Fatty acid synthase as a new therapeutic target for HER2-positive gastric cancer
por: Castagnoli, Lorenzo, et al.
Publicado: (2023)

New Therapeutic Strategies in Advanced Nonoperable or Metastatic HER2-positive Breast Cancer
por: Lüftner, Diana, et al.
Publicado: (2021)

From Anti-HER-2 to Anti-HER-2-CAR-T Cells: An Evolutionary Immunotherapy Approach for Gastric Cancer
por: Sun, Jiangang, et al.
Publicado: (2022)

Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent?
por: Ishimine, Yu, et al.
Publicado: (2015)

An Insight into the Novel Immunotherapy and Targeted Therapeutic Strategies for Hepatocellular Carcinoma and Cholangiocarcinoma
por: Trifylli, Eleni-Myrto, et al.
Publicado: (2022)

Curcumin mediates oxaliplatin-acquired resistance reversion in colorectal cancer cell lines through modulation of CXC-Chemokine/NF-κB signalling pathway
por: Ruiz de Porras, Vicenç, et al.
Publicado: (2016)

HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer
por: Kaito, Akio, et al.
Publicado: (2019)

MSI and EBV Positive Gastric Cancer’s Subgroups and Their Link with Novel Immunotherapy
por: Rodriquenz, Maria Grazia, et al.
Publicado: (2020)

Targeting HER2-positive gastric cancer with a novel (18)F-labeled Z(HER2:342) probe
por: Pan, Yunyun, et al.
Publicado: (2019)

Pharmacological ascorbate as a novel therapeutic strategy to enhance cancer immunotherapy
por: Zaher, Amira, et al.
Publicado: (2022)

HER2-positive gastric cancer identified by serum HER2: A case report
por: SAITO, MAYUKO, et al.
Publicado: (2016)

Clinical Impact of New Treatment Strategies for HER2-Positive Metastatic Breast Cancer Patients with Resistance to Classical Anti-HER Therapies
por: Tapia, Marta, et al.
Publicado: (2023)

Brain Metastases in HER2-Positive Breast Cancer: Current and Novel Treatment Strategies
por: Garcia-Alvarez, Alejandro, et al.
Publicado: (2021)

HER2 Positive Gastric Carcinomas and Their Clinico-Pathological Characteristics
por: Ognjenovic, Ljubomir, et al.
Publicado: (2018)

Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer
por: Soo Park, Ji, et al.
Publicado: (2017)

Challenges and future of HER2-positive gastric cancer therapy
por: Ma, Chenzhe, et al.
Publicado: (2023)

HER2-Positive Breast Cancer Immunotherapy: A Focus on Vaccine Development
por: Arab, Atefeh, et al.
Publicado: (2020)

Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives
por: Krasniqi, E., et al.
Publicado: (2019)

Overcoming therapeutic MAb resistance in agressive HER2 positive breast carcinomas by adoptive immunotherapy using optizimed effectors cells
por: Valsesia-Wittmann, Sandrine, et al.
Publicado: (2013)

Combined targeting of HER-2 and HER-3 represents a promising therapeutic strategy in colorectal cancer
por: Conradi, Lena-Christin, et al.
Publicado: (2019)

Novel therapeutic strategies in human malignancy: combining immunotherapy and oncolytic virotherapy
por: Sampath, Padma, et al.
Publicado: (2015)

Novel ADCs and Strategies to Overcome Resistance to Anti-HER2 ADCs
por: Díaz-Rodríguez, Elena, et al.
Publicado: (2021)

Characterizing Metastatic HER2-Positive Gastric Cancer at the CDH1 Haplotype
por: Caggiari, Laura, et al.
Publicado: (2017)

A novel treatment strategy for lapatinib resistance in a subset of HER2-amplified gastric cancer
por: Ning, Gang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_80hl7dj129h6h4to30c631uk2i